Table 4 Impact of the dual therapy on analytical parameters
Baseline | 24 weeks | P value | |
|---|---|---|---|
CD4 lymphocytes (cells/uL) | 630 | 667 | 0.071* |
CD4/CD8 Ratio | 0.749 | 0.788 | 0.004 |
Creatinine (mg/dL) | 0.944 | 0.977 | 0.001 |
Glucose (mg/dL) | 95.2 | 96.5 | 0.057 |
Total Cholesterol/HDL | 4,13 | 4,10 | 0.107 |
Total Cholesterol (mg/dL) | 183 | 196 | < 0.001* |
HDL-cholesterol (mg/dL) | 48 | 52 | 0.005 |
LDL-cholesterol (mg/dL) | 107 | 124 | 0.003* |
Triglycerides (mg/dL) | 144 | 157 | 0.172 |
Bilirubin (mg/dL) | 0.77 | 0.64 | 0.827 |
GOT (U/L) | 40.9 | 30.8 | 0.031 |
GPT (U/L) | 45.9 | 30.3 | 0.011 |
GGT (U/L) | 57.5 | 59.4 | 0.040 |
Alkaline Phosphatase (U/L) | 98 | 93 | 0.026 |
Hemoglobin (g/dL) | 15 | 14.8 | 0.009 |
Platelets (×10^3/μL) | 190 | 189 | 0.346 |